stoxline Quote Chart Rank Option Currency Glossary
Arrowhead Pharmaceuticals, Inc. (ARWR)
24.53  0.74 (3.11%)    12-07 16:00
Open: 23.79
High: 24.93
Volume: 1,264,373
Pre. Close: 23.79
Low: 23.52
Market Cap: 2,635(M)
Technical analysis
2023-12-07 4:19:03 PM
Short term     
Mid term     
Targets 6-month :  30.66 1-year :  34.68
Resists First :  26.25 Second :  29.7
Pivot price 26.47
Supports First :  20.67 Second :  17.19
MAs MA(5) :  23.97 MA(20) :  26.56
MA(100) :  27.98 MA(250) :  31.16
MACD MACD :  -0.7 Signal :  -0.2
%K %D K(14,3) :  35.9 D(3) :  36.1
RSI RSI(14): 45
52-week High :  42.47 Low :  20.67
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ARWR ] has closed above bottom band by 31.5%. Bollinger Bands are 112.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 23.94 - 24.05 24.05 - 24.16
Low: 23.07 - 23.2 23.2 - 23.32
Close: 23.58 - 23.78 23.78 - 23.97
Company Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Headline News

Thu, 07 Dec 2023
Arrowhead Pharma: Transition To Commercialization (NASDAQ:ARWR) - Seeking Alpha

Fri, 01 Dec 2023
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript - Yahoo Finance

Fri, 01 Dec 2023
Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed - Seeking Alpha

Fri, 01 Dec 2023
Premarket Mover: Arrowhead Pharmaceuticals Inc (ARWR) Up 2.12% - InvestorsObserver

Wed, 29 Nov 2023
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results - Business Wire

Wed, 29 Nov 2023
Arrowhead Pharmaceuticals Inc Reports Fiscal 2023 Year-End Results - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 107 (M)
Shares Float 104 (M)
Held by Insiders 4.9 (%)
Held by Institutions 70.7 (%)
Shares Short 7,880 (K)
Shares Short P.Month 7,130 (K)
Stock Financials
EPS -1.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.52
Profit Margin -85.3 %
Operating Margin -673 %
Return on Assets (ttm) -17.6 %
Return on Equity (ttm) -59.4 %
Qtrly Rev. Growth -49 %
Gross Profit (p.s.) 2.26
Sales Per Share 2.24
EBITDA (p.s.) -1.81
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -12.78
PEG Ratio -1
Price to Book value 9.69
Price to Sales 10.94
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android